129 related articles for article (PubMed ID: 28841513)
21. Design of inhibitors of BCRP/ABCG2.
Juvale K; Wiese M
Future Med Chem; 2015 Aug; 7(12):1521-7. PubMed ID: 26293476
[TBL] [Abstract][Full Text] [Related]
22. The More the Better-Investigation of Polymethoxylated
Stockmann P; Kuhnert L; Leinung W; Lakoma C; Scholz B; Paskas S; Mijatović S; Maksimović-Ivanić D; Honscha W; Hey-Hawkins E
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678870
[TBL] [Abstract][Full Text] [Related]
23. Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
Jabor Gozzi G; Bouaziz Z; Winter E; Daflon-Yunes N; Aichele D; Nacereddine A; Marminon C; Valdameri G; Zeinyeh W; Bollacke A; Guillon J; Lacoudre A; Pinaud N; Cadena SM; Jose J; Le Borgne M; Di Pietro A
J Med Chem; 2015 Jan; 58(1):265-77. PubMed ID: 25272055
[TBL] [Abstract][Full Text] [Related]
24. Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists.
Silbermann K; Li J; Namasivayam V; Baltes F; Bendas G; Stefan SM; Wiese M
J Med Chem; 2020 Sep; 63(18):10412-10432. PubMed ID: 32787102
[TBL] [Abstract][Full Text] [Related]
25. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
[TBL] [Abstract][Full Text] [Related]
26. Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
Roussel E; Moréno A; Altounian N; Philouze C; Pérès B; Thomas A; Renaudet O; Falson P; Boumendjel A
Eur J Med Chem; 2020 Sep; 202():112503. PubMed ID: 32653696
[TBL] [Abstract][Full Text] [Related]
27. 4-Substituted-2-phenylquinazolines as inhibitors of BCRP.
Juvale K; Wiese M
Bioorg Med Chem Lett; 2012 Nov; 22(21):6766-9. PubMed ID: 23017888
[TBL] [Abstract][Full Text] [Related]
28. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
Ishikawa T; Nakagawa H
J Exp Ther Oncol; 2009; 8(1):5-24. PubMed ID: 19827267
[TBL] [Abstract][Full Text] [Related]
29. ABCG2/BCRP: Specific and Nonspecific Modulators.
Peña-Solórzano D; Stark SA; König B; Sierra CA; Ochoa-Puentes C
Med Res Rev; 2017 Sep; 37(5):987-1050. PubMed ID: 28005280
[TBL] [Abstract][Full Text] [Related]
30. 2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations.
Kathawala RJ; Li T; Yang D; Guo HQ; Yang DH; Chen X; Cheng C; Chen ZS
J Cell Biochem; 2017 Aug; 118(8):2420-2429. PubMed ID: 28120346
[TBL] [Abstract][Full Text] [Related]
31. Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
Winter E; Devantier Neuenfeldt P; Chiaradia-Delatorre LD; Gauthier C; Yunes RA; Nunes RJ; Creczynski-Pasa TB; Di Pietro A
J Med Chem; 2014 Apr; 57(7):2930-41. PubMed ID: 24611893
[TBL] [Abstract][Full Text] [Related]
32. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of Homoverrucosanoid-Derived Esters and Evaluation as MDR Modulators.
Schäfer A; Köhler SC; Lohe M; Wiese M; Hiersemann M
J Org Chem; 2017 Oct; 82(19):10504-10522. PubMed ID: 28949536
[TBL] [Abstract][Full Text] [Related]
34. ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions.
Glavinas H; Kis E; Pál A; Kovács R; Jani M; Vági E; Molnár E; Bánsághi S; Kele Z; Janáky T; Báthori G; von Richter O; Koomen GJ; Krajcsi P
Drug Metab Dispos; 2007 Sep; 35(9):1533-42. PubMed ID: 17537873
[TBL] [Abstract][Full Text] [Related]
35. Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
Antoni F; Bause M; Scholler M; Bauer S; Stark SA; Jackson SM; Manolaridis I; Locher KP; König B; Buschauer A; Bernhardt G
Eur J Med Chem; 2020 Apr; 191():112133. PubMed ID: 32105979
[TBL] [Abstract][Full Text] [Related]
36. Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.
Köhler SC; Silbermann K; Wiese M
Eur J Med Chem; 2016 Nov; 124():881-895. PubMed ID: 27676469
[TBL] [Abstract][Full Text] [Related]
37. New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.
Krapf MK; Gallus J; Vahdati S; Wiese M
J Med Chem; 2018 Apr; 61(8):3389-3408. PubMed ID: 29547272
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
Winter E; Lecerf-Schmidt F; Gozzi G; Peres B; Lightbody M; Gauthier C; Ozvegy-Laczka C; Szakacs G; Sarkadi B; Creczynski-Pasa TB; Boumendjel A; Di Pietro A
J Med Chem; 2013 Dec; 56(24):9849-60. PubMed ID: 24304387
[TBL] [Abstract][Full Text] [Related]
39. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.
Anreddy N; Patel A; Zhang YK; Wang YJ; Shukla S; Kathawala RJ; Kumar P; Gupta P; Ambudkar SV; Wurpel JN; Chen ZS; Guo H
Oncotarget; 2015 Nov; 6(36):39276-91. PubMed ID: 26515463
[TBL] [Abstract][Full Text] [Related]
40. Tetrahydroquinoline/4,5-Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2).
Vesga LC; Kronenberger T; Tonduru AK; Kita DH; Zattoni IF; Bernal CC; Bohórquez ARR; Mendez-Sánchez SC; Ambudkar SV; Valdameri G; Poso A
ChemMedChem; 2021 Sep; 16(17):2686-2694. PubMed ID: 33844464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
